Impact of Dietary Inflammatory Potential on Breast Cancer Risk
Part of paid clinical trials in Columbus, Ohio.
- Sponsor
- Ohio State University Comprehensive Cancer Center
- Study ID
- NCT05178498
- Status
- Recruiting
Conditions
- Breast Atypical Ductal Hyperplasia
- Breast Atypical Lobular Hyperplasia
- Breast Carcinoma
- Breast Lobular Carcinoma In Situ
- Breast Sclerosing Adenosis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Follow-Up — PROCEDUREUndergo follow up
- Physical Examination — PROCEDUREComplete physical measurements
- Questionnaire Administration — OTHERComplete questionnaires
Study Details
This study evaluates the association of dietary inflammatory potential with breast cancer risk. Information collected in this study may help doctors to identify modifiable risk factors, screen high risk patients early, improve prevention strategies, and provide timely intervention for early therapeutic management as needed.
Key Dates
- Start date
- Oct 25, 2023
- Status verified
- Feb 2025
- Primary completion
- Dec 31, 2035
- Completion
- Dec 31, 2035
Study Design
- Enrollment
- 960 participants (estimated)
Arms
- Arm: Observational (physical exam, questionnaire)Patients complete physical measurements every 6 months and complete questionnaires annually for 5 years. Patients are followed up annually in years 5-10.
Primary Outcome Measure
Time to breast cancer events during study follow up [ Time Frame: Up to 10 years ]
Central Contacts
- The Ohio State University Comprehensive Cancer Center800-293-5066
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | Sagar D. Sardesai, MSPH, PhD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Columbus, OH
By condition
By specialty
By research site
Related Studies
- Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast CancerPHASE2 · Recruiting · National Cancer Institute (NCI) · Duarte, California
- Mobile Health for Adherence in Breast Cancer PatientsRecruiting · ECOG-ACRIN Cancer Research Group · Fairbanks, Alaska
- Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE TrialPHASE2 · Recruiting · National Cancer Institute (NCI) · Tucson, Arizona
- Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk ReductionPHASE2 · Recruiting · National Cancer Institute (NCI) · Kansas City, Kansas